The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
NCT Number: NCT03871725
Sonodynamic therapy (SDT) is a new treatment for carotid atherosclerotic plaque. The purpose of this study is to evaluate the safety and initial effectiveness of this technique.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 1
Harbin, Heilongjiang, 150000, China
Carotid atherosclerotic plaque is an important cause of ischemic stroke. Treatments for patients with carotid plaque include lifestyle changes, medical management(such as control of hyperlipidemia, hypertension, and diabetes) and carotid revascularization(carotid endarterectomy or carotid artery stenting). Studies have suggested that plaque morphology and composition are important determinants of plaque stability, using serial MR imaging of the carotid artery allowed observation of changes in plaque composition. Contrast enhanced ultrasound (CEUS) is a well accepted technique for detection of intraplaque neovascularization(IPN) in carotid atherosclerotic disease. The purpose of this trial is to evaluate the safety and initial effectiveness of SDT. The SDT can induce macrophage elimination and inhibit matrix degradation, which will promote plaque lipid depletion, inflammation level decrease and changes in other plaque tissue components, leading to plaque stabilization and reduction.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in plaque MaxWT (maximum wall thickness) as assessed by MRI.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in intraplaque hemorrhage (IPH) volume as assessed by MRI.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in LRNC (lipid-rich necrotic core) volume as assessed by MRI.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in LM (loose matrix) volume as assessed by MRI.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in calcification (CA) volume as assessed by MRI.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in plaque volume(mm3) as assessed by MRI
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
The changes in normalised maximal video-intensity enhancement (MVE) are calculated to quantify the density of IPN as assessed by CEUS.
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
incidence of major adverse cardiovascular and cerebrovascular events(MACCE)
Time frame: Measured at Baseline, 1, 3, 6, and 9 months
Allergic to sunshine,hepatic or renal dysfunction,thyroid dysfunction
First Affiliated Hospital of Harbin Medical University
Other
Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques
Acronym: SMART-C
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03982420
Arterial Occlusive Diseases, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT04053166
Brain Diseases, Cardiovascular Diseases
Bron, France
View Trial DetailsNCT04470687
Arterial Occlusive Diseases, Atheroma; Carotid Artery
Paris, France
View Trial DetailsNCT05230576
Brain Diseases, Cardiovascular Diseases
Guangzhou, Guangdong, China
View Trial Details